DE69434021D1 - Tuberkulose-impfstoff - Google Patents

Tuberkulose-impfstoff

Info

Publication number
DE69434021D1
DE69434021D1 DE69434021T DE69434021T DE69434021D1 DE 69434021 D1 DE69434021 D1 DE 69434021D1 DE 69434021 T DE69434021 T DE 69434021T DE 69434021 T DE69434021 T DE 69434021T DE 69434021 D1 DE69434021 D1 DE 69434021D1
Authority
DE
Germany
Prior art keywords
tuberculosis
mycobacterium
mpt64
vaccination
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434021T
Other languages
English (en)
Other versions
DE69434021T2 (de
Inventor
Peter Andersen
Ase Bengaard Andersen
Kare Haslov
Anne Lund Sorensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Statens Serum Institut Kopenhagen/copenhagen Dk
Original Assignee
Statens Serum Institut SSI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Serum Institut SSI filed Critical Statens Serum Institut SSI
Publication of DE69434021D1 publication Critical patent/DE69434021D1/de
Application granted granted Critical
Publication of DE69434021T2 publication Critical patent/DE69434021T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69434021T 1993-07-02 1994-07-01 Tuberkulose-impfstoff Expired - Lifetime DE69434021T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK93798A DK79893D0 (da) 1993-07-02 1993-07-02 New vaccine
DK79893 1993-07-02
PCT/DK1994/000273 WO1995001441A1 (en) 1993-07-02 1994-07-01 Tuberculosis vaccine

Publications (2)

Publication Number Publication Date
DE69434021D1 true DE69434021D1 (de) 2004-10-28
DE69434021T2 DE69434021T2 (de) 2005-09-01

Family

ID=8097685

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69434021T Expired - Lifetime DE69434021T2 (de) 1993-07-02 1994-07-01 Tuberkulose-impfstoff

Country Status (10)

Country Link
EP (2) EP1508339A1 (de)
AT (1) ATE277181T1 (de)
AU (1) AU682879B2 (de)
CA (1) CA2165949C (de)
DE (1) DE69434021T2 (de)
DK (2) DK79893D0 (de)
ES (1) ES2229220T3 (de)
NZ (1) NZ267984A (de)
PT (1) PT706571E (de)
WO (1) WO1995001441A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6991797B2 (en) 1993-07-02 2006-01-31 Statens Serum Institut M. tuberculosis antigens
US6641814B1 (en) 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
ES2313719T3 (es) 1993-11-23 2009-03-01 The Regents Of The University Of California Productos extracelulares abundantes y procedimiento de produccion y uso de los mismos.
US6752993B1 (en) 1993-11-23 2004-06-22 The Regents Of The University Of California Abundant extracellular product vaccines and methods for their production and use
US7300660B2 (en) 1993-11-23 2007-11-27 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
US6338852B1 (en) 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
TR200806258T2 (tr) * 1995-09-01 2008-10-21 Corixa Corporation Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler
EP1712629A3 (de) * 1995-09-01 2009-09-09 Corixa Corporation Verbindungen und Verfahren zur Diagnose von Tuberkulose
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
AU765833B2 (en) * 1995-09-01 2003-10-02 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
ES2378051T3 (es) * 1995-09-01 2012-04-04 Corixa Corporation Compuestos y métodos para el diagnóstico de la tubercolosis.
GB9526178D0 (en) 1995-12-21 1996-02-21 Taylor John Hermon Novel polynuceotides and polypeptides in pathogenic mycobacteria and their use as diagnostics,vaccines and targets for chemotherapy
US6013660A (en) * 1996-10-02 2000-01-11 The Regents Of The University Of California Externally targeted prophylactic and chemotherapeutic method and agents
CZ126699A3 (cs) * 1996-10-11 1999-09-15 Corixa Corporation Polypeptid obsahující antigenní část rozpustného antigenu M. tuberculosis nebo variantu uvedeného antigenu, molekula DNA kódující tento polypeptid, expresivní vektor, hostitelská buňka, způsoby diagnostiky infekce M. tuberculosis a diagnostické kity
GB9624456D0 (en) 1996-11-25 1997-01-15 Isis Innovation Assay method
US6544522B1 (en) * 1998-12-30 2003-04-08 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6982085B2 (en) 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
ATE370236T1 (de) * 1997-04-02 2007-09-15 Statens Seruminstitut Nukleinsäure- und polypeptidfragmente von m. tuberculosis
US7037510B2 (en) 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
AU750173B2 (en) * 1997-11-10 2002-07-11 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
WO1999045119A2 (en) * 1998-03-06 1999-09-10 Statens Serum Institut Production of mycobacterial polypeptides by lactic acid bacteria
GB9806093D0 (en) 1998-03-20 1998-05-20 Taylor John Hermon Diagnostics and vaccines for mycobacterial infections of animals and humans
CN1629185B (zh) * 1998-04-07 2011-11-02 科里克萨公司 结核杆菌抗原融合蛋白及其应用
AU6480999A (en) * 1998-11-04 2000-05-22 Isis Innovation Limited Tuberculosis diagnostic test
US20020131976A1 (en) 1998-12-23 2002-09-19 Ajit Lalvani Tuberculosis vaccine
US6465633B1 (en) 1998-12-24 2002-10-15 Corixa Corporation Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
EP1183044B1 (de) * 1999-05-12 2007-10-10 Statens Serum Institut Adjuvanskombinationen zur immunisierung und vakzine
US6649170B1 (en) 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
CA2376723A1 (en) * 1999-06-18 2000-12-28 James G. Ferry Compositions and methods for the prevention, treatment and detection of tuberculosis and other diseases
WO2002004018A2 (en) * 2000-07-10 2002-01-17 Colorado State University Research Foundation Mid-life vaccine and methods for boosting anti-mycobacterial immunity
WO2004099771A1 (en) 2003-05-08 2004-11-18 Statens Serum Institut A new specific epitope based immunological diagnosis of tuberculosis
CA2586620C (en) 2004-11-16 2014-06-03 Crucell Holland B.V. Multivalent vaccines comprising recombinant viral vectors
US8398991B2 (en) * 2005-06-22 2013-03-19 Institut Pasteur Modified ESAT-6 molecules and improved vaccine strains of Mycobacterium bovis BCG
CN100999550B (zh) * 2006-01-10 2010-10-06 中国人民解放军第三○九医院 结核分枝杆菌融合蛋白及其应用
GB0618127D0 (en) * 2006-09-14 2006-10-25 Isis Innovation Biomarker
EP2142931B1 (de) 2007-05-08 2016-06-22 Prionics AG Verfahren zur diagnose von tuberkulose
KR20170071507A (ko) 2014-10-23 2017-06-23 퀴아젠 사이언시스, 엘엘씨 펩티드 조성물 및 그의 용도
US10370419B2 (en) 2014-12-09 2019-08-06 The Board Of Regents Of The University Of Textas System Tuberculosis vaccine compositions and related methods
CN106248934B (zh) * 2016-08-25 2018-04-06 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌抗原蛋白Rv0446c及其T细胞表位肽的应用
CN106405107B (zh) * 2016-08-31 2018-04-06 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌抗原蛋白Rv2941及其T细胞表位肽的应用
RU2631607C1 (ru) * 2016-11-22 2017-09-25 Владислав Николаевич Ласкавый Средство для профилактики лейкоза крупного рогатого скота и способ его применения

Also Published As

Publication number Publication date
EP1508339A1 (de) 2005-02-23
AU7068894A (en) 1995-01-24
CA2165949A1 (en) 1995-01-12
AU682879B2 (en) 1997-10-23
EP0706571B1 (de) 2004-09-22
CA2165949C (en) 2011-06-07
PT706571E (pt) 2005-02-28
WO1995001441A1 (en) 1995-01-12
DK0706571T3 (da) 2005-01-31
DE69434021T2 (de) 2005-09-01
EP0706571A1 (de) 1996-04-17
NZ267984A (en) 1997-09-22
ATE277181T1 (de) 2004-10-15
DK79893D0 (da) 1993-07-02
ES2229220T3 (es) 2005-04-16

Similar Documents

Publication Publication Date Title
ATE277181T1 (de) Tuberkulose-impfstoff
EP1523331B1 (de) Therapeutisches vakzin gegen tuberkulosis
WO1996015241A3 (en) A polynucleotide tuberculosis vaccine
PT2006395E (pt) Quadro de leitura aberto de m. tuberculosis rv2660c e suas utilizações
DE69839426T2 (de) Nukleotidsequenzen, die für sekretierte polypeptide aus mycobacterium kodieren, vektoren, die diese enthalten, und anwendungen zur diagnostik und verhütung von tuberkulose
ATE526994T1 (de) Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten
WO2002004018A8 (en) Mid-life vaccine and methods for boosting anti-mycobacterial immunity
DK524289A (da) Fremgangsmaade til diagnosticering for og vaccine mod mycobakterier
Vordermeier et al. Toward the development of diagnostic assays to discriminate between Mycobacterium bovis infection and bacille Calmette-Guerin vaccination in cattle
AU2529095A (en) Vaccine against mycobacterial infections
HK1081437A1 (en) Use of mycobacterial antigen mpb64 in the manufacture of a product for topical detection of active tuberculosis
Gilot et al. Comparative analysis of three sensitins used in cutaneous testing for tuberculosis and paratuberculosis in cattle
BAESS et al. Classification of Mycobacterium simiae by means of comparative reciprocal intradermal sensitin testing on guinea‐pigs and deoxyribonucleic acid hybridization
Hernandez-Pando et al. Recombinant BCG vaccine candidates
Austrian A brief history of pneumococcal vaccines
Teng et al. Immunogenicity of heparin-binding hemagglutinin expressed by Pichia pastoris GS115 strain
WO2000044392A3 (en) Identification of specific differentially expressed mycobacterial antigens
Borek Medical microbiology. vol. 2. Immunization against bacterial disease: edited by CSF Easmon and J. Jeljaszewicz. Academic Press, London, 1983 (304 pp., illus.)£ 32.00/$55.00
Singh et al. Mycobacterium phlei: A novel immunogenic strain against M. tuberculosis infection in experimental animals.
Ridell Crossreactivity between Mycobacterium leprae and various actinomycetes and related organisms
Verma et al. Immunodominant antigens as biomarkers of Mycobacterium tuberculosis and M. bovis: Mini Review
Plouffe et al. Serological differences in Legionella pneumophila infections
Ridell et al. Immunodiffusion analyses of environmental mycobacteria isolated in Zaïre
CA2205175A1 (en) A polynucleotide tuberculosis vaccine
Diky Characteristic of main properties of" LK-Kharkov" vaccinal strain tuberculosis mycobacteria.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: STATENS SERUM INSTITUT, KOPENHAGEN/COPENHAGEN, DK

8364 No opposition during term of opposition